|
NOL9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.3818999995171E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.71743999999308E-05 |
| Normal-vs-Stage2 |
9.569400E-04 |
| Normal-vs-Stage3 |
7.65510000000358E-05 |
| Normal-vs-Stage4 |
1.17859999981818E-07 |
| Stage1-vs-Stage2 |
8.053200E-01 |
| Stage1-vs-Stage3 |
6.634200E-01 |
| Stage1-vs-Stage4 |
9.584300E-03 |
| Stage2-vs-Stage3 |
9.460800E-01 |
| Stage2-vs-Stage4 |
1.254640E-01 |
| Stage3-vs-Stage4 |
6.826400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.92489999997869E-06 |
| Normal-vs-AfricanAmerican |
1.608110E-02 |
| Normal-vs-Asian |
3.821800E-04 |
| Caucasian-vs-AfricanAmerican |
6.447800E-01 |
| Caucasian-vs-Asian |
7.435600E-01 |
| AfricanAmerican-vs-Asian |
5.205200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.37779999995502E-06 |
| Normal-vs-Female |
1.26850000004008E-06 |
| Male-vs-Female |
6.213600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.62430000000869E-05 |
| Normal-vs-Age(41-60Yrs) |
2.24689999994698E-06 |
| Normal-vs-Age(61-80Yrs) |
4.05270000003455E-06 |
| Normal-vs-Age(81-100Yrs) |
5.258100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.125200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.307400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.277000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.783800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.644800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.770000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.748000E-02 |
| Classical-VS-Follicular |
6.399300E-03 |
| Classical-VS-Other |
9.139600E-02 |
| Classical-VS-Normal |
8.33270000000219E-05 |
| Tall-VS-Follicular |
9.938400E-01 |
| Tall-VS-Other |
4.470800E-01 |
| Tall-VS-Normal |
1.392940E-04 |
| Follicular-VS-Other |
4.591200E-01 |
| Follicular-VS-Normal |
5.13220000053494E-07 |
| Other-VS-Normal |
4.819000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.58671999999083E-05 |
| Normal-vs-N1 |
1.52559999999635E-06 |
| N0-vs-N1 |
1.945420E-01 |
|
|
